Acinom Healthcare

What Acinom Healthcare does

Acinom Healthcare is a privately held Indian pharmaceutical company headquartered in Chandigarh with a WHO-GMP and ISO 9001:2008 certified manufacturing facility in Baddi, Himachal Pradesh. Established in 2007, the company manufactures and supplies a broad portfolio of generic pharmaceutical formulations spanning more than 20 therapeutic segments, including antibiotics, gastro/PPI, cardiology/antidiabetic, neuro-psychiatric, orthopaedics, nutraceuticals, derma, dental, and I.V. fluids, with dosage forms covering tablets (including dispersible, enteric-coated, and combinations), capsules, syrups, injections, ointments, eye/nasal drops, powders, sachets, and suspensions.

The company operates on a multi-channel distribution model anchored by a PCD (Propaganda Cum Distribution) pharma franchise system under which it grants area-wise monopoly rights and marketing support (visual aids, MR bags, samples, training) to thousands of franchise partners across India. It also runs direct institutional supply to Indian Defence services, healthcare departments, and hospitals, engages in international exports of psychiatric and general formulations, and provides third-party/contract manufacturing services for other pharmaceutical brands using its certified Baddi facility. Operational features include a Schedule M compliant plant (effective January 2026), same-day dispatch, a live online order-tracking system, and FSSAI certification for nutraceutical production.

Revenue mechanics combine franchise partner stocking orders (initial investments typically ₹50,000–₹2,00,000), institutional and government tenders, export contracts, and contract-manufacturing fees. Pricing for franchise partnerships is quote-based and not publicly disclosed, while end-product MRPs on the listed catalogue range from roughly ₹37 to ₹600. Customer segments span pharma entrepreneurs and franchise seekers (primary), government healthcare institutions, international organizations, third-party manufacturing clients, and end consumers served through the franchise channel.

Name

Acinom Healthcare

Legal name

Acinom Healthcare

Website

https://acinomhealthcare.com

Company type

Private

Founded year

2007

Operating status

Operating

Headcount range

251–500 employees

Short description

Acinom Healthcare is an Indian pharmaceutical manufacturer and PCD franchise company (est. 2007) that produces generic formulations across 20+ therapeutic segments at a WHO-GMP facility in Baddi, distributing them through thousands of franchise partners, government institutional supply, and international exports.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (424210), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Generic Finished Dosage Form (FDF) Manufacturing (HLAIABAH)

akta.pro secondary industries

Specialty Pharmaceutical Distributors (HLAIAJAB), GMP Scale-Up, Tech Transfer & Process Validation (PPQ) (HLAGAHAL)

Keywords

• Generic pharmaceutical manufacturing
• PCD pharma franchise
• Third-party contract manufacturing
• WHO-GMP certified formulations
• Pharmaceutical distribution

Headquarters

HQ city

Chandigarh

HQ country

India

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Supply Chain, Personnel, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. PCD Pharma Franchise Fees and Product Sales: Acinom Healthcare generates revenue primarily through franchise partnership fees and the sale of pharmaceutical products to franchise partners. Franchise partners purchase products at wholesale/distributor rates and resell them in their designated territories, generating margins. The company also earns from direct institutional sales to government bodies (Defence, healthcare departments, hospitals) and international exports.
2. Third-Party / Contract Manufacturing: Acinom Healthcare provides third-party (contract) manufacturing services, manufacturing pharmaceutical products for other brands under their names. The company offers integrated contract manufacturing and development services from ideas to high-volume commercial production, including packaging and monopoly-based product rights.
3. Export of Pharmaceutical Products: The company exports pharmaceutical products to international markets, contributing a substantial portion of overall revenues. Exports cover psychiatric medicines and general pharmaceutical formulations to prominent international organizations.

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels6 records

Core offering

Acinom Healthcare manufactures and supplies generic pharmaceutical formulations including tablets, capsules, syrups, injections, ointments, eye/nasal drops, I.V. fluids, derma products, and nutritional supplements across 20+ therapeutic segments. The company distributes primarily through a PCD franchise model that recruits entrepreneurs with area-wise monopoly rights, while also providing third-party contract manufacturing services for other pharma brands and supplying government institutions and international markets. Manufacturing is carried out at a WHO-GMP and ISO 9001:2008 certified facility in Baddi, Himachal Pradesh.

Product overview

Acinom Healthcare operates as a WHO-GMP certified pharmaceutical company established in 2007, offering a comprehensive portfolio of generic pharmaceutical products across multiple therapeutic segments. The company provides PCD pharma franchise opportunities alongside third-party manufacturing services from their WHO-GMP certified facilities. Their product portfolio spans tablets (including disperse, enteric-coated, and combination formulations), capsules, syrups, injections, ointments, derma products, eye/nasal drops, I.V fluids, and nutritional supplements. Key product brands include cardiovascular/diabetic medications (TENGPURE, TENGPURE-M500, MONRAB, MONRAB-D), antibiotics (ROXINOM, YELCEF, FIX, NOMXIME, NOMCLOX-CLAV variants), gastrointestinal products (MONPAN, DIGEST), and specialty formulations like CHYMONOM (enzyme therapy). The company differentiates through monopoly-based franchise rights, comprehensive marketing support including MR bags, samples, and promotional materials, and same-day dispatch capabilities. Their manufacturing facility in Baddi, Himachal Pradesh operates under Schedule M compliant processes, producing products for domestic Indian markets and international exports to government institutions and global markets.

Differentiator

Problem solved

Functional benefit

Brands

• Dclonom-TH: Pharmaceutical product
• Nomraft
• Nompar IV
• DOXICIL-LB
• TELNIKO
• CHYMONOM
• TENGPURE
• TENGPURE-M500
• MONRAB
• MONRAB-D
• MONPAN-D
• MONPAN-40
• ROXINOM-500
• ROXINOM-CV
• ROXINOM-250
• YELCEF-100
• YELCEF-200
• YELCEF-CLAV
• YELCEF-O
• FIX-100
• FIX-200
• NOMXIME-100
• NOMXIME-200
• NOMXIME-CLAV
• NOMXIME-LB
• NOMXIME-O
• NOMCLOX-CLAV
• NOMCLOX-CLAV LB
• MONDANS
• CINMON-D
• DIGEST
• OFLONOM-200

Products and services

• Dclonom-TH Pharmaceutical tablet product in Acinom Healthcare's core product range, sold to franchise partners and institutional buyers in India.
• Nomraft Pharmaceutical product in Acinom Healthcare's product portfolio, manufactured at the company's WHO-GMP facility and sold via franchise and institutional channels.
• Nompar IV Intravenous pharmaceutical product offered by Acinom Healthcare for use in clinical and hospital settings.
• DOXICIL-LB Antibiotic pharmaceutical tablet combining doxycycline with Lactobacillus, manufactured by Acinom Healthcare for distribution via franchise and institutional channels.
• CHYMONOM (Trypsin-Chymotrypsin 100000 AU) Enzyme tablet formulation containing trypsin and chymotrypsin with 100,000 AU potency for orthopaedic therapeutic use, packed in blister packaging. Sold to franchise partners, hospitals, and export customers.
• TENGPURE (Teneligliptin 20mg) DPP-4 inhibitor tablet containing teneligliptin 20mg for diabetes management, packaged in ALU ALU strips. Marketed under the cardiology/antidiabetic therapeutic segment.
• TENGPURE-M500 (Teneligliptin 20mg + Metformin 500mg SR) Combination antidiabetic tablet combining teneligliptin 20mg with metformin 500mg sustained release, packaged as ALU ALU 10x10 strips for diabetes management.
• MONRAB (Rabeprazole 20mg) Gastro-resistant tablet containing rabeprazole 20mg, a proton pump inhibitor for acid-related disorders in the gastro/PPI therapeutic segment.
• ROXINOM-500 (Cefuroxime 500mg) Cephalosporin antibiotic tablet containing cefuroxime axetil 500mg in ALU ALU with mono carton packaging for the antibiotics therapeutic segment.
• PCD Pharma Franchise Program A PCD (Propaganda Cum Distribution) pharma franchise program recruiting entrepreneurs and distributors across India with area-wise monopoly rights, a ready-made product portfolio, marketing support materials (visual aids, MR bags, samples, brochures), and training programmes. Franchise partners must hold a valid drug license and GST registration; entry-level investment starts around ₹50,000.
• Third-Party / Contract Manufacturing Contract manufacturing services for pharmaceutical brands seeking to outsource production of tablets, capsules, syrups, injections, and specialty formulations. Services cover integrated product development from concept to high-volume commercial production, packaging, and quality assurance, with monopoly-based product rights offered to clients.

Quantifiable outcome

• Same-day product dispatch with delivery within 24 hours
• +2 more outcomes

Named customers6 records

Segments5 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Scale indicators5 records

Recent moves5 records

Expansion highlights6 records

Direct peers

• Unichem Laboratories: Indian generic pharmaceutical manufacturer producing formulations across multiple therapeutic categories with domestic and export sales — closest mid-cap analogue to Acinom in terms of portfolio breadth and scale.
• Macleods Pharmaceuticals: Private Indian manufacturer of generics across antibiotics, cardiovascular and CNS, with significant domestic franchise distribution. Closely mirrors Acinom's combination of in-house manufacturing and broad PCD/generic distribution in India.
• Ajanta Pharma: Indian specialty generic manufacturer with branded generics, contract manufacturing and emerging-market exports — overlapping directly with Acinom's domestic franchise + export + third-party manufacturing model.
• Indoco Remedies: Mid-sized Indian generic manufacturer producing formulations and APIs for domestic and export markets across multiple therapeutic segments, similar in scale and breadth to Acinom.
• FDC Limited: Indian manufacturer of generics, particularly anti-infectives and ophthalmics, with established domestic and export distribution. Comparable therapeutic and franchise footprint.

Broad incumbents

• Zydus Lifesciences: Large Indian pharma group with domestic formulations, contract manufacturing and exports. Comparable manufacturing + franchise + export mix though at significantly larger scale.
• Cipla: One of India's largest generic pharma companies with broad formulation portfolio and significant global exports. Overlaps with Acinom on multiple therapeutic segments and export channel, but at vastly greater scale.
• Alkem Laboratories: Large Indian generic manufacturer with strong domestic franchise presence, anti-infective and chronic therapy portfolios and own manufacturing. Comparable at the product and channel level though materially larger.
• Lupin: Major Indian generic manufacturer with branded generics, domestic franchise distribution and global exports across antibiotics, cardiovascular and CNS — the same therapeutic mix Acinom serves.
• Mankind Pharma: One of India's largest domestic-focused generic and OTC pharma companies with deep PCD franchise reach. Much larger than Acinom but operates in the same generic + franchise playbook.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/AcinomHealthca2

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Acinom Healthcare